BioSpace News Archive

New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a Certified B Corporation™ business

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that Professor Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, will deliver presentations at two upcoming medical meetings.

Scott Sigman, M.D., today announced positive results from a randomized clinical pilot study for COVID-19 pneumonia patients treated with MLS Laser Therapy.

ProCure Proton Therapy Center welcomes Nicholas J. DeNunzio, MD, PhD, to a growing list of tri-state physicians with expertise in treating cancer patients with proton therapy.

New company launched by healthcare startup veterans Derek Streat and Sean O’Connor; backed by Define Ventures, Frist Cressey Ventures, Kaiser Permanente Ventures, SpringRock Ventures and Providence Ventures

Kastle Systems announced today that it is providing property owners, tenants and employees with a new ability to add vaccination status as a factor to control access to offices and buildings, an important step in helping workers get back to the office safely.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) announced today that it has acquired a line of peripheral support catheters from WavePoint Medical, LLC.

Urology of San Antonio, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Philippines has secured 7 million additional doses of COVID-19 Vaccine Moderna through a new supply agreement, bringing its confirmed order commitment up to 20 million doses.

We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.